{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:46:20Z","timestamp":1791359180031,"version":"4.3.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>The causal relationship of lipoprotein(a) with cardiovascular disease has been established. However, clinical impacts of lipoprotein(a) levels on adverse vascular events in patients with established coronary artery disease who are undergoing statin treatment have not been fully elucidated. We measured lipoprotein(a) levels of 668 consecutive patients with ST-elevated myocardial infarction upon admission and reevaluated lipoprotein(a) of 189 of these patients during statin treatment at least 6 months later than the date of index ST-elevated myocardial infarction. Changes in lipoprotein(a) and associations between lipoprotein(a) levels and the incidence of major adverse cardiac and cerebrovascular event for 3 years were examined. Lipoprotein(a) at baseline was an independent predictor of 3-year major adverse cardiac and cerebrovascular event after ST-elevated myocardial infarction. Levels of lipoprotein(a) at follow-up were slightly but significantly elevated despite improvements in other lipid parameters due to statin treatment. Furthermore, higher levels of lipoprotein(a) achieved with statin treatment were also associated with the subsequent incidence of major adverse cardiac and cerebrovascular event over 3 years, regardless of whether or not the LDL-cholesterol levels were below 100 mg\/dl. In conclusion, lipoprotein(a) levels during lipid management by statin are also predictive of adverse vascular events in Japanese patients with ST-elevated myocardial infarction.<\/jats:p>","DOI":"10.1097\/mca.0000000000000798","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:17:47Z","timestamp":1570029467000},"page":"600-607","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic impact of lipoprotein(a) levels during lipid management with statins after ST-elevation acute myocardial infarction"],"prefix":"10.1097","volume":"30","author":[{"given":"Takayuki","family":"Mitsuda","sequence":"first","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Center, Anjo Kosei Hospital, Anjo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takemoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Center, Anjo Kosei Hospital, Anjo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Koyasu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Center, Anjo Kosei Hospital, Anjo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Center, Anjo Kosei Hospital, Anjo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Watarai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Center, Anjo Kosei Hospital, Anjo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1253\/circj.CJ-09-0619","article-title":"Trends in acute myocardial infarction incidence and mortality over 30 years in Japan: report from the MIYAGI-AMI registry study.","volume":"74","author":"Takii","year":"2010","journal-title":"Circ J"},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa0908610","article-title":"Population trends in the incidence and outcomes of acute myocardial infarction.","volume":"362","author":"Yeh","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1253\/circj.CJ-11-1059","article-title":"Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction.","volume":"77","author":"Nakatani","year":"2013","journal-title":"Circ J"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1161\/ATVBAHA.114.303932","article-title":"Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from study of coronary atheroma by intravascular ultrasound: effect of rosuvastatin versus atorvastatin.","volume":"34","author":"Puri","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.jacc.2014.08.045","article-title":"Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.","volume":"64","author":"Komukai","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","article-title":"Lipoprotein(a): an elusive cardiovascular risk factor.","volume":"24","author":"Berglund","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOL.0b013e328308b622","article-title":"The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity.","volume":"19","author":"Tsimikas","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a Mendelian randomisation analysis.","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00380-016-0823-0","article-title":"Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction.","volume":"31","author":"Mitsuda","year":"2016","journal-title":"Heart Vessels"},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","article-title":"Report of the committee on the classification and diagnostic criteria of diabetes mellitus.","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan.","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk.","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5551\/jat.15867","article-title":"Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u20132012","volume":"20","author":"Teramoto","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias.","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease.","volume":"63","author":"O\u2019Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1194\/jlr.M008961","article-title":"Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy.","volume":"51","author":"Nicholls","year":"2010","journal-title":"J Lipid Res"},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2017.06.026","article-title":"Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN.","volume":"263","author":"Puri","year":"2017","journal-title":"Atherosclerosis"},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study.","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race\/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas heart study.","volume":"119","author":"Tsimikas","year":"2009","journal-title":"Circulation"},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the multi-ethnic study of atherosclerosis.","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamacardio.2017.3833","article-title":"Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial.","volume":"3","author":"Schwartz","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2013.01.014","article-title":"Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies.","volume":"227","author":"Qin","year":"2013","journal-title":"Atherosclerosis"},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2014.10.015","article-title":"Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention.","volume":"115","author":"Konishi","year":"2015","journal-title":"Am J Cardiol"},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"\u2018LDL-C\u2019 = LDL-C + lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/Kexin type 9 era of potent LDL-C lowering.","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jacc.2012.04.038","article-title":"Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Borden","year":"2011","journal-title":"N Engl J Med"},{"key":"R35-20230928","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor\u2019s role.","volume":"57","author":"Raal","year":"2016","journal-title":"J Lipid Res"},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R37-20230928","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects.","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R38-20230928","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.21037\/jtd.2017.01.40","article-title":"Lipoprotein(a) and inhibitors of proprotein convertase subtilisin\/Kexin type 9","volume":"9","author":"Kotani","year":"2017","journal-title":"J Thorac Dis"},{"key":"R39-20230928","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"R40-20230928","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinbiochem.2010.06.019","article-title":"Percutaneous coronary intervention results in acute increases in native and oxidized lipoprotein(a) in patients with acute coronary syndrome and stable coronary artery disease.","volume":"43","author":"Wang","year":"2010","journal-title":"Clin Biochem"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T03:13:28Z","timestamp":1695870808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000798","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}